Intravenous VAL-1221 Lafora Expanded Access Protocol

Lafora Disease Clinical Trial

— LEAP  

Official title:

Intravenous VAL-1221 Lafora Expanded Access Protocol (LEAP)

Clinical Trial Details — Status: Available

Administrative data

• NCT number: NCT05930223
• Other study ID #: VAL1221-LEAP-01
• Status: Available

Study information

• Verified date: June 2023
• Source: Parasail, LLC
• Contact: Dustin Armstrong, PhD
• Phone: (617) 462-3084
• Email: dustin.armstrong[@]parasailllc.com
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

Only qualified physicians treating a Lafora Disease patient may request VAL-1221 Expanded Access treatment under the Parasail Lafora Expanded Access Protocol (LEAP). According to FDA guidance, this protocol can enroll up to 10 patients. However, individual patient inclusion will ultimately be dependent on protocol eligibility, site geography, treatment requirements, and available supply of the investigational therapy. Inquiring physicians can submit a request by contacting the Central Contact personnel listed below in Contacts/Locations.

Recruitment information / eligibility

• Status: Available
• Enrollment: 0
• Gender: All
• Age group: 12 Years to 28 Years

Eligibility

Inclusion Criteria:

• Documented genetic diagnosis of Lafora Disease (LD) based on likely pathogenic or pathogenic variants in both alleles of either the EPM2A or the EPM2B gene
• Mid-stage in evolution of LD between 12 and 28 years of age
• Able and willing to comply with the protocol, including travel to Protocol Center,

procedures, measurements and visits, including:

• Adequately supportive psychosocial circumstances, in the opinion of the Investigator
• Caregiver/trial partner committed to facilitate patient's involvement in the study who is reliable, competent, at least 18 years of age

Exclusion Criteria:

• Have any other conditions, which, in the opinion of the Investigator or Sponsor would make the participant unsafe for inclusion or could interfere with the participant participating in or completing the protocol

Related Conditions & MeSH terms

• Lafora Disease

Intervention

Drug:
• VAL-1221
VAL-1221 20mg/kg intravenous (IV) infusion every other week

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Parasail, LLC